EGFR and non-small cell lung carcinoma: Our early work shows that osimertinib exerts its inhibitory effects against the growth of EGFR-mutant NSCLC cells primarily through inducing apoptosis; this involves upregulation of Bim and downregulation of Mcl-1 by the modulation of MEK-dependent protein degradation [5].